U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C13H15N3O2S
Molecular Weight 277.342
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of K-858

SMILES

CC(=O)NC1=NN(C(C)=O)C(C)(S1)C2=CC=CC=C2

InChI

InChIKey=JEFVYQYZCAVNTP-UHFFFAOYSA-N
InChI=1S/C13H15N3O2S/c1-9(17)14-12-15-16(10(2)18)13(3,19-12)11-7-5-4-6-8-11/h4-8H,1-3H3,(H,14,15,17)

HIDE SMILES / InChI
K-858 is a small molecule inhibitor of Eg5 (kinesin spindle protein), a mitotic kinesin that plays an essential role in establishing mitotic spindle bipolarity. K-858 blocked centrosome separation, activated the spindle checkpoint, and induced mitotic arrest in cells accompanied by the formation of monopolar spindles. K858 induces mitotic arrest, apoptosis, and cell growth inhibition in cancer cells. K-858 exhibited potent antitumor activity in xenograft models of cancer, and induced the accumulation of mitotic cells with monopolar spindles in tumor tissues.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
1.3 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
K858, a novel inhibitor of mitotic kinesin Eg5 and antitumor agent, induces cell death in cancer cells.
2009 May 1
STLC-resistant cell lines as tools to classify chemically divergent Eg5 targeting agents according to their mode of action and target specificity.
2013 Nov 15
Synthesis and pharmacological screening of a large library of 1,3,4-thiadiazolines as innovative therapeutic tools for the treatment of prostate cancer and melanoma.
2015 Nov 13

Sample Use Guides

K858 exhibits antitumor activity and induces mitotic arrest in human xenograft tumor models: K858 at doses of 150 mg/kg administered orally twice for 5 days suppressed tumor growth in an A2780 ovarian cancer xenograft model, In a HCT116 colon cancer xenograft model, at a dose of 100 mg/kg twice a day orally for 5 days, K858 also exhibited antitumor activity.
Route of Administration: Oral
K858 induces mitotic arrest with EC50 1.6 uM and cell growth inhibition with GI50 0.98 uM
Name Type Language
K-858
Common Name English
ACETAMIDE, N-(4-ACETYL-4,5-DIHYDRO-5-METHYL-5-PHENYL-1,3,4-THIADIAZOL-2-YL)-
Systematic Name English
Code System Code Type Description
CAS
72926-24-0
Created by admin on Sat Dec 16 08:01:57 GMT 2023 , Edited by admin on Sat Dec 16 08:01:57 GMT 2023
PRIMARY
PUBCHEM
2930014
Created by admin on Sat Dec 16 08:01:57 GMT 2023 , Edited by admin on Sat Dec 16 08:01:57 GMT 2023
PRIMARY
FDA UNII
ZA4OIM722G
Created by admin on Sat Dec 16 08:01:57 GMT 2023 , Edited by admin on Sat Dec 16 08:01:57 GMT 2023
PRIMARY